Document:

Amendment No. 1 to the Master Separation Agreement

 Exhibit 10.2 
 AMENDMENT NO. 1 
 TO 
 THE MASTER SEPARATION AGREEMENT 
 THIS AMENDMENT NO. 1 TO THE MASTER SEPARATION
AGREEMENT (this “Amendment”), dated as of November 6, 2006, is among Lazard Ltd, a Bermuda exempted company (“Lazard Ltd”), Lazard Group LLC, a Delaware limited liability company (“Lazard
Group”), and LAZ-MD Holdings LLC, a Delaware limited liability company (“LAZ-MD”). 
 WHEREAS, Lazard Ltd, Lazard
Group, LAZ-MD and LFCM Holdings LLC, a Delaware limited liability company (“LFCM”) are parties to that certain Master Separation Agreement, dated as of May 10, 2005 (the “Agreement”); and 
 WHEREAS, each of Lazard Ltd, Lazard Group and LAZ-MD desires to amend Article VIII of the Agreement as set forth in this Amendment. 
 NOW, THEREFORE, the Agreement is hereby amended as follows: 
 1. Amendment of Section 8.2(b). Section 8.2(b) of the Agreement is hereby amended by deleting clauses (ii) and (iii) thereof and replacing them in their entirety with the following:

 “(ii) Except as otherwise provided in this clause (ii), each Exchangeable MD Member who shall be entitled to make an
Elective Exchange and desires to exchange such member’s Exchangeable Interest (or portion thereof) so exchangeable (an “Electing Member”) shall prepare and deliver to LAZ-MD and each of Lazard Ltd Sub A and Lazard Ltd Sub B a
written request signed by such Electing Member (A) stating the amount of Units underlying the Exchangeable Interest that such Electing Member desires to exchange, (B) stating whether the Electing Member shall elect to have such exchange
consummated on (x) the Applicable Exchange Date, (y) any day selected by the Exchanging Member during the period of five Business Days following the filing by Lazard Ltd with the SEC of its periodic filings on Form 10-Q or Form 10-K
(excluding, with respect to filings on Form 10-Q, filings for the quarterly period ended March 31 of each year) at any time after the applicable Accelerated Exchange Date (the “Periodic Filing Exchange Date”) or (z) if applicable
the date immediately prior to the date of sale in any registered offering to be conducted in connection with such Elective Exchange of the shares of Lazard Ltd Common Stock to be issued in such Elective Exchange to such Electing Member (such date
under this clause (z), the “Registration Exchange Date”, and the date selected by the Exchanging Member, the “Exchange Effective Date”), and (C) certifying that such Electing Member is entitled to exchange the portion of the
Exchangeable Interest that such member desires to exchange and that such Electing Member is the beneficial owner of such Exchangeable Interest (each such request, an “Exchange Request”). A properly completed Exchange Request must be
delivered to LAZ-MD and each of Lazard Ltd Sub A and Lazard Ltd Sub B (1) with respect to MD Exchanges occurring on the anniversary dates of the IPO, not less than 30 days or more than 60 days prior to the anniversary date on which such
Electing Member desires to effect the Exchanges in accordance with this Section and (2) with respect to MD Exchanges occurring on a Periodic Filing Exchange Date, not less than 20 days or more than 30 days prior to such Periodic Filing Exchange
Date. With respect to MD Exchanges occurring on the Registration Exchange Date, any properly completed notice to Lazard Ltd by which the Electing Member elects to register, or include in any registration, the shares of Lazard Ltd Common Stock to be
issued in such Elective Exchange pursuant to the LAZ-MD Stockholders’ Agreement shall be deemed to meet the notice and delivery requirements of an Exchange Request. Each of Lazard Ltd Sub A and Lazard Ltd Sub B shall have the right to determine
whether any Exchange Request is proper under this Article VIII or to waive any infraction of these procedures. Once delivered, an Exchange Request shall be irrevocable. 

 (iii) Each Elective Exchange shall be consummated effective as of the close of Lazard
Ltd’s business on the applicable Exchange Effective Date (such time, the “Elective Exchange Effective Time”), and the Electing Member shall be deemed to have become the holder of record of the applicable shares of Lazard Ltd
Common Stock at such Elective Exchange Effective Time (or, in the case of an Electing Member who is an Electing LAZ-MD Exchange Member (as defined in the LAZ-MD Operating Agreement), at the time of receipt of such shares of Lazard Ltd Common Stock)
and all rights of the Electing Member in respect of the portion of the Exchangeable Interest so exchanged shall terminate at such Elective Exchange Effective Time. In the event that an Electing Member shall select the Registration Exchange Date as
the Exchange Effective Date in accordance with clause (ii) above, such Elective Exchange shall be null and void (and such Electing Member shall continue to hold the applicable Exchangeable Interest) in the event that the sale shall not occur in
the applicable registered offering to be conducted in connection with such Elective Exchange for any reason (including as the result of any cutbacks in or the termination of such registered offering).” 
 2. Amendment to Section 8.8. Section 8.8 of the Agreement is hereby amended by deleting such Section 8.8 and replacing it in its
entirety with the following: 
 “Section 8.8 Adjustments to LAZ-MD Exchange Ratio. The LAZ-MD Exchange Ratio shall
be appropriately adjusted in the event of any transfer, sale or other disposition of any Lazard Group Common Interests by LAZ-MD or any combination of outstanding Lazard Group Common Units held by LAZ-MD or any combination of outstanding Lazard
Group Common Units held by LAZ-MD into a smaller number of Lazard Group Common Units, in each case to the extent it would result in the number of Lazard Group Common Units held by LAZ-MD being less than the number of outstanding LAZ-MD Class II
Units (other than, for the avoidance of doubt, pursuant to any Exchange). Any such transfer, sale or other disposition of any such Lazard Group Common Interests by LAZ-MD or any such combination of Lazard Group Common Units shall not affect or
otherwise alter or adjust the Lazard Group Exchange Ratio except as provided in Section 8.9.” 
 3. Addition of
Section 8.9(d). Section 8.9 of the Agreement is hereby amended by adding a new clause (d) at the end thereof: 
 “(d) In the event that Lazard Group shall combine the outstanding Lazard Group Common Units held by LAZ-MD into a smaller number of Lazard Group Common Units, the Lazard Group Exchange Ratio in effect immediately prior to such action
shall be adjusted so that the holder of an Exchangeable Interest thereafter exchanged in accordance with this Article VIII may receive the number of shares of Lazard Ltd Common Stock that it would have owned immediately following such action if it
had exchanged its Exchangeable Interests in full for shares of Lazard Ltd Common Stock immediately prior to such action.” 
 4.
Addition of Section 8.11. Article VIII of the Agreement is hereby amended by adding a new Section 8.11 at the end thereof: 
 “Section 8.11 Consent Right of Holders of Exchangeable Interests to Selected Amendments of this Article VIII. In addition to any approvals required under Section 11.5, any amendment to Article VIII (and the
defined terms to the extent used in this Article VIII) that materially and adversely impacts the rights of any holder of an Exchangeable Interest as in effect immediately prior to such amendment shall not be enforceable against that holder unless
that holder consented to such amendment if such amendment shall not apply to and affect the rights of all holders of Exchangeable Interests equally (for the avoidance of doubt, any such amendment shall not apply to and affect the rights of all
holders equally if it affects the holders’ rights granted under Article VIII differently, including, without limitation, with respect to their employment status, length of employment or ownership (or right to acquire) of Exchangeable Interests
or the shares issuable thereon) (it being understood and agreed that this Section 8.11 may not be amended without the consent of Lazard Ltd, LAZ-MD and each holder of Exchangeable Interests). Each holder of Exchangeable Interests shall be a
third party beneficiary of the provisions of this Section 8.11.” 
 5. Binding Effect. (a) This Amendment and all of
the provisions hereof shall be binding upon and inure to the benefit of the parties hereto and LFCM and their respective successors and permitted assigns, but neither this 

  

 2 

 
Amendment nor any of the rights, interests and obligations hereunder shall be assigned or otherwise transferred, in whole or in part, by any party without
the prior written consent of each of the parties to the Agreement. This Amendment and all of the provisions hereof shall be binding simultaneously with, and the effectiveness of this Amendment and all of the provisions hereof shall be conditioned
upon, the effectiveness of the Amended and Restated Stockholders’ Agreement to be entered into by and among Lazard Ltd, LAZ-MD Holdings and the individuals listed on the signature page thereto. 
 (b) This Amendment is solely for the benefit of the parties and LFCM (subject to Section 8.10 of the Agreement) and is not intended
to confer upon any other persons any rights or remedies hereunder. 
 6. Execution in Counterparts. This Amendment may be executed in
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 7.
Invalidity of Provisions. If any term or other provision of this Amendment is invalid, illegal or incapable of being enforced by any applicable rule of law or public policy, all other conditions and provisions of this Amendment shall
nevertheless remain in full force and effect so long as the economic or legal substance of the transactions contemplated hereby is not affected in any manner materially adverse to any party. Upon such determination that any term or other provision
is invalid, illegal or incapable of being enforced, the parties hereto shall negotiate in good faith to modify this Amendment so as to effect the original intent of such parties as closely as possible in an acceptable manner to the end that
transactions contemplated hereby are fulfilled to the extent possible. 
 8. Agreement in Effect. Except as hereby amended, the
Agreement shall remain in full force and effect. 
 9. Governing Law. This Amendment shall be governed by and construed in accordance
with the laws of the State of Delaware (other than the laws regarding choice of laws and conflicts of laws that would apply the substantive laws of any other jurisdiction) as to all matters, including matters of validity, construction, effect,
performance and remedies. 
  

 3 

 IN WITNESS WHEREOF, the parties hereto have caused this Amendment to be duly executed as of the date set
forth above. 
  

			
	LAZARD LTD
		
	By:	 	/s/    MICHAEL J.
CASTELLANO        
	Name:	 	Michael J. Castellano
	Title:	 	Chief Financial Officer
	
	LAZARD GROUP LLC
		
	By:	 	/s/    MICHAEL J.
CASTELLANO        
	Name:	 	Michael J. Castellano
	Title:	 	Chief Financial Officer
	
	LAZ-MD HOLDINGS LLC
		
	By:	 	/s/    LARRY GRAFSTEIN        
	Name:	 	Larry Grafstein
	Title:	 	DirectorAmended and Restated Stockholders' Agreement

 Exhibit 10.4 
 AMENDED AND RESTATED STOCKHOLDERS’ AGREEMENT 
 This AMENDED AND RESTATED STOCKHOLDERS’
AGREEMENT (including Appendix A hereto, as such Appendix A may be amended from time to time pursuant to the provisions hereof, this “Agreement”), is made and entered into as of November 6, 2006, by and among LAZ-MD Holdings
LLC, a Delaware limited liability corporation (“LAZ-MD”), the individuals listed on the signature page hereto, and, solely for the purposes of Articles I, II, IV and V hereto, Lazard Ltd, an exempted Bermuda limited company
(“Lazard Ltd”). 
 W I T N E S S E T H: 
 WHEREAS, the Covered Persons (as defined below) are beneficial owners of Class II Interests (as defined below) of LAZ-MD; and 
 WHEREAS, LAZ-MD holds the outstanding share of Class B Common Stock, par value $0.01 per share, of Lazard Ltd (“Class B Common Stock”); and 
 WHEREAS, LAZ-MD and Lazard Ltd are parties to that certain Master Separation Agreement (the “Master Separation Agreement”), dated as of
May 10, 2005, with Lazard Group (as defined below) and LFCM Holdings LLC, a Delaware limited liability company, as amended, pursuant to which, inter alia, the parties thereto have agreed to the exchange of Class II Interests effectively
for Class A Common Stock, par value $0.01 per share, of Lazard Ltd (the “Common Stock”); and 
 WHEREAS, the parties
hereto have entered into that certain Stockholders’ Agreement, dated as of May 10, 2005 (the “Original Agreement”), in order to provide for certain voting arrangements with respect to the Class B Common Stock and to grant
certain registration rights to the Covered Persons; and 
 WHEREAS, the parties to the Original Agreement desire to amend and restate the
Original Agreement to read in its entirety as set forth herein. 
 NOW, THEREFORE, in consideration of the premises and of the mutual
agreements, covenants and provisions herein contained, the parties hereto agree as follows: 
 ARTICLE I 
 DEFINITIONS AND OTHER MATTERS 
 Section
1.1 Definitions. Capitalized terms used in this Agreement without other definition shall, unless expressly stated otherwise, have the meanings specified in this Section 1.1: 
 (a) “Agreement” has the meaning ascribed to such term in the Recitals. 
 (b) A “beneficial owner” of a security includes any person who, directly or indirectly, through any contract,
arrangement, understanding, relationship or otherwise has or shares: (i) voting power, which includes the power to vote, or to direct the voting of, such security and/or (ii) investment power, which includes the power to dispose, or to
direct the disposition of, such security, but for purposes of this Agreement a person shall not be deemed a beneficial owner of (A) Covered Interests solely by virtue of the application of Exchange Act Rule 13d-3(d) or Exchange Act Rule 13d-5
as in effect on the date hereof, (B) Covered Interests solely by virtue of the possession of the legal right to vote securities under applicable state or other law (such as by proxy or power of attorney), or (C) Covered Interests held of
record by a “private foundation” subject to the requirements of Section 509 of the Code. “Beneficially own” and “beneficial ownership” shall have correlative meanings. 
 (c) “Board” means the Board of Directors of LAZ-MD. 

 (d) “Board Review” has the meaning set forth in Section 5.4(b).

 (e) “Class B Common Stock” has the meaning ascribed to such term in the Recitals. 
 (f) “Class II Interest” means, with respect to any Covered Person, such Covered Person’s “Class II
Interest” as defined in the Operating Agreement. 
 (g) “Common Stock” has the meaning ascribed to such
term in the Recitals. 
 (h) “Continuing Provisions” has the meaning ascribed to such term in
Section 5.1(b). 
 (i) “Covered Interest” means, with respect to a Covered Person, such Covered
Person’s Class II Interest or Lazard Group Common Interest, as the case may be. 
 (j) “Covered Persons”
means those persons from time to time who are listed on Appendix A hereto and who have become parties to this Agreement, in each case in accordance with the terms hereof. 
 (k) “Damages” has the meaning set forth in Section 4.6. 
 (l) “Delaware Arbitration Act” has the meaning set forth in Section 5.4(d). 
 (m) “Demand Notice” has the meaning set forth in Section 4.2(a). 
 (n) “Demand Registration” has the meaning set forth in Section 4.2(a). 
 (o) “Demand Requesting Covered Persons” has the meaning set forth in Section 4.2(a). 
 (p) “Disputes” has the meaning set forth in Section 5.4(b). 
 (q) “Exchange Act” means the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated
thereunder, and as each of the foregoing may be further amended from time to time. 
 (r) “Filing” has the
meaning set forth in Section 3.5. 
 (s) “Governmental Authority” means any national, local or foreign
(including U.S. federal, state or local) or supranational (including European Union) governmental, judicial, administrative or regulatory (including self-regulatory) agency, commission, department, board, bureau, entity or authority of competent
jurisdiction. 
 (t) “ICC” has the meaning set forth in Section 5.4(b). 
 (u) “ICC Rules” has the meaning set forth in Section 5.4(b). 
 (v) “Indemnified Party” has the meaning set forth in Section 4.8. 
 (w) “Indemnifying Party” has the meaning set forth in Section 4.8. 
 (x) “IPO Date” means the closing date of the initial public offering of the Common Stock, which occurred on the date
hereof. 
 (y) “LAZ-MD” has the meaning ascribed to such term in the Recitals. 
 (z) “Lazard Ltd” has the meaning ascribed to such term in the Recitals. 
 (aa) “Lazard Group” means Lazard Group LLC, a Delaware limited liability company. 
 (bb) “Lazard Group Common Interest” means, with respect to any Covered Person, such Covered Person’s “Common
Interest” as defined in the Lazard Group Operating Agreement. 
 (cc) “Lazard Group Operating Agreement”
means the Operating Agreement of Lazard Group LLC, as amended and restated as of May 10, 2005, and as amended and further amended from time to time hereafter. 
 (dd) “LFCM” means LFCM Holdings LLC, a Delaware limited liability company. 
 (ee) “LFCM Operating Agreement” means the Operating Agreement of LFCM Holdings LLC, as amended and restated as of
May 10, 2005, and as amended and further amended from time to time hereafter. 
  

 2 

 (ff) “Master Separation Agreement” has the meaning ascribed to such term
in the Recitals. 
 (gg) “Minimum Demand Number” means, as of any particular date, that number of shares of
Common Stock equal to the lesser of (a) the quotient obtained by dividing (i) $50,000,000 by (ii) the Stock Price as of such date; provided, however, that on and after the six months following the nine-year anniversary
of the IPO Date, “$50,000,000” in this definition shall be replaced with “$20,000,000,” and (b) 2,000,000. 
 (hh) “Minimum Share Number” means that number of shares of Common Stock equal to the lesser of (a) the quotient obtained by dividing (i) $50,000,000 by (ii) the Stock Price as of the applicable anniversary of
the IPO Date and (b) 2,000,000. 
 (ii) “Operating Agreement” means the Operating Agreement of LAZ-MD
Holdings LLC, as amended and restated as of May 10, 2005, and as amended and further amended from time to time hereafter. 
 (jj) “Periodic Filing Date” means the date of the first to occur following the applicable anniversary of the IPO Date of the filing of the Form 10-K or Form 10-Q of Lazard Ltd with the SEC under the Exchange Act.

 (kk) “Permitted Transfer” has the meaning set forth in Section 5.1(c). 
 (ll) “Piggyback Registration” has the meaning set forth in Section 4.3(a). 
 (mm) “Preliminary Vote” has the meaning set forth in Section 3.1. 
 (nn) “Public Offering” means an underwritten public offering pursuant to an effective registration statement under the
Securities Act, other than pursuant to a registration statement on Forms S-4 or S-8 or any similar or successor form. 
 (oo)
“Registration Expenses” means any and all expenses incident to the performance of or compliance with any registration or marketing of securities, including all (i) registration and filing fees, and all other fees and expenses
payable in connection with the listing of securities on any securities exchange or automated interdealer quotation system, (ii) fees and expenses of compliance with any securities or “blue sky” laws (including reasonable fees and
disbursements of counsel in connection with “blue sky” qualifications of the securities registered), (iii) expenses in connection with the preparation, printing, mailing and delivery of any registration statements, prospectuses and
other documents in connection therewith and any amendments or supplements thereto, (iv) security engraving and printing expenses, (v) internal expenses of Lazard Ltd (including, without limitation, all salaries and expenses of its officers
and employees performing legal or accounting duties), (vi) reasonable fees and disbursements of counsel for Lazard Ltd and customary fees and expenses for independent certified public accountants retained by Lazard Ltd (including the expenses
relating to any comfort letters or costs associated with the delivery by independent certified public accountants of any comfort letters requested pursuant to Section 4.5(h)), (vii) reasonable fees and expenses of any special experts
retained by Lazard Ltd in connection with such registration, (viii) reasonable fees, out-of-pocket costs and expenses of the Covered Persons, including one counsel for all of the Covered Persons participating in the offering selected by the
Covered Persons holding the majority of the Registrable Securities to be sold for the account of all Covered Persons in the offering, (ix) fees and expenses in connection with any review by the NASD of the underwriting arrangements or other
terms of the offering, and all fees and expenses of any “qualified independent underwriter,” including the fees and expenses of any counsel thereto, (x) fees and disbursements of underwriters customarily paid by issuers or sellers of
securities, but excluding any underwriting fees, discounts and commissions attributable to the sale of Registrable Securities, (xi) costs of printing and producing any agreements among underwriters, underwriting agreements, any “blue
sky” or legal investment memoranda and any selling agreements and other documents in connection with the offering, sale or delivery of the Registrable Securities, (xii) transfer agents’ and registrars’ fees and expenses and the
fees and expenses of any other agent or trustee appointed in connection with such offering, (xiii) expenses relating to any analyst or investor presentations or any “road shows” undertaken in connection with the registration,
marketing or selling of the Registrable Securities, (xiv) fees and expenses payable in connection with any ratings of the 

  

 3 

 
Registrable Securities, including expenses relating to any presentations to rating agencies and (xv) all out-of-pocket costs and expenses incurred by
Lazard Ltd or its appropriate officers in connection with their compliance with Section 4.5(l). 
 (pp)
“Registrable Securities” means all shares of Common Stock (and any securities issued or issuable in respect of such Common Stock by way of conversion, exchange, stock dividend, split or combination, recapitalization, merger,
amalgamation, consolidation, other reorganization or otherwise) that are received by Covered Persons (or then eligible for receipt by Covered Persons pursuant to an MD Exchange under the Master Separation Agreement (to the extent that such Covered
Persons’ LAZ-MD Holdings Class II Interests or Lazard Group Common Interests (or applicable portions thereof) is exchangeable pursuant to an MD Exchange), assuming compliance with applicable procedural requirements) in exchange for
(1) Class II Interests of Covered Persons or (2) Lazard Group Common Interests of Covered Persons (collectively, “MD Exchangeable Interests”) that are received in exchange for such Covered Persons’ Class II Interests,
in each case, pursuant to Section 7.04 of the Operating Agreement (“Covered Shares”) and that may be deemed “restricted securities” as defined in Rule 144(a)(3) under the Securities Act; provided, that Covered
Shares that are eligible for sale under Rule 144(k) of the Securities Act shall cease to be Registrable Securities; provided, however, that in the event that a Covered Person beneficially owns Covered Shares that, in the aggregate,
total a number of shares of Common Stock equal to or greater than the quotient obtained by dividing (x) $25,000,000 by (y) the Stock Price as of five Business Days prior to the expected effectiveness of the applicable registration
statement, any such Covered Shares that would have ceased to be Registrable Securities pursuant to the immediately foregoing proviso shall continue to be Registrable Securities so long as such Covered Person beneficially owns Covered Shares totaling
at least such value as of each such applicable measurement date. A share of Common Stock (and any securities issued or issuable in respect of such Common Stock by way of conversion, exchange, stock dividend, split or combination, recapitalization,
merger, amalgamation, consolidation, other reorganization or otherwise) shall cease to be a Registrable Security upon any sale of such share of Common Stock (or, as applicable, such securities issued or issuable in respect of Common Stock by way of
conversion, exchange, stock dividend, split or combination, recapitalization, merger, amalgamation, consolidation, other reorganization or otherwise) to the public pursuant to, and in accordance with, a registration statement, including any
registration statements contemplated hereby, or pursuant to Rule 144 under the Securities Act, Regulation S under the Securities Act or Section 4(1) of the Securities Act. 
 (qq) “Restricted Person” means any person that is not (i) a Covered Person or (ii) a director, officer or
employee of LAZ-MD acting in such person’s capacity as a director, officer or employee. 
 (rr) “SEC”
means the Securities and Exchange Commission. 
 (ss) “Securities Act” means the Securities Act of 1933, as
amended, and the rules and regulations promulgated thereunder, and as each of the foregoing may be further amended from time to time. 
 (tt) “Stock Price” means, as of any particular date, the closing price as of such date of a share of Common Stock on the primary national securities exchange on which the Common Stock is traded, as
reported by Bloomberg L.P. or, if Bloomberg L.P. is not available, as determined by another reputable third-party information source selected by Lazard Ltd. 
 (uu) “Subsidiary” means, with respect to any person, any corporation, limited liability company, company, partnership,
trust, association or other legal entity or organization of which such person (either directly or through one or more subsidiaries of such person) (a) owns, directly or indirectly, a majority of the capital stock or other equity interests the
holders of which are generally entitled to vote for the election of the board of directors or other governing body of such corporation, limited liability company, partnership, trust, association or other legal entity or organization, or (b) is
otherwise entitled to exercise (1) a majority of the voting power generally in the election of the board of directors or other governing body of such corporation, limited liability company, partnership, trust, association or other legal entity
or organization or (2) control of such corporation, limited liability company, partnership, trust, association or other legal entity or organization. 
  

 4 

 (vv) “Transfer” means, with respect to any Covered Interests,
(i) when used as a verb, to sell, assign, dispose of, exchange, pledge, encumber, hypothecate or otherwise transfer such Covered Interests or any participation or interest therein, whether directly or indirectly, or agree or commit to do any of
the foregoing, and (ii) when used as a noun, a direct or indirect sale, assignment, disposition, exchange, pledge, encumbrance, hypothecation, or other transfer of such Covered Interests or any participation or interest therein or any agreement
or commitment to do any of the foregoing. 
 Section 1.2 Definitions Generally. Wherever required by the context of this Agreement,
the singular shall include the plural and vice versa, and the masculine gender shall include the feminine and neuter genders and vice versa, and references to any agreement, document or instrument shall be deemed to refer to such agreement, document
or instrument as amended, supplemented or modified from time to time. When used herein: 
 (a) the word “or” is not
exclusive; 
 (b) the words “including,” “includes,” “included” and “include” are
deemed to be followed by the words “without limitation”; 
 (c) the terms “herein,” “hereof” and
“hereunder” and other words of similar import refer to this Agreement as a whole and not to any particular section, paragraph or subdivision; 
 (d) the word “person” means any individual, corporation, limited liability company, trust, joint venture, association, company, partnership or other legal entity or a government or any department or agency
thereof or self-regulatory organization; and 
 (e) all section, paragraph or clause references not attributed to a particular
document shall be references to such parts of this Agreement, and all exhibit, annex and schedule references not attributed to a particular document shall be references to such exhibits, annexes and schedules to this Agreement. 
 ARTICLE II 
 REPRESENTATIONS AND
WARRANTIES 
 Section 2.1 Representations and Warranties of Covered Persons. 
 (a) Each Covered Person severally represents and warrants to each of LAZ-MD and Lazard Ltd, as of the date hereof and as of the date of
the registration of any of such Covered Person’s Registrable Securities and as of the date of any Demand Notice delivered by or on behalf of such Covered Person, that: such Covered Person has good, valid and marketable title to the Covered
Interests and Registrable Securities, as applicable, in each case free and clear of any pledge, lien, security interest, charge, claim, equity or encumbrance of any kind, other than (A) pursuant to this Agreement or another agreement with the
issuer of the Covered Interest or Registrable Securities, as the case may be, by which such Covered Person is bound and to which the Covered Interest or Registrable Securities, as applicable, are subject, and (B) in the case of Covered
Interests, the Operating Agreement or Lazard Group Operating Agreement, as applicable; and 
 (b) Each Covered Person
severally represents and warrants to each of LAZ-MD and Lazard Ltd, as of the date hereof and as of the date of the registration of any of such Covered Person’s Registrable Securities and as of the date of any Demand Notice delivered by or on
behalf of such Covered Person, if the Covered Person is other than a natural person, with respect to subsections (i) through (x), and if the Covered Person is a natural person, with respect to subsections (iv) through (x) only:
(i) such Covered Person is duly organized and validly existing in good standing under the laws of the jurisdiction of such Covered Person’s formation; (ii) such Covered Person has full right, power and authority to enter into and
perform this Agreement; (iii) the execution and delivery of this Agreement and the performance of the transactions contemplated herein have been duly authorized, and no further proceedings on the part of such Covered Person are necessary to
authorize the execution, delivery and performance of this Agreement; and this Agreement has been duly executed by such Covered Person; (iv) the person signing this Agreement on behalf of such Covered Person has been duly authorized by such
Covered Person to do so; (v) this 

  

 5 

 
Agreement constitutes the legal, valid and binding obligation of such Covered Person, enforceable against such Covered Person in accordance with its terms
(subject to bankruptcy, insolvency, fraudulent transfer, reorganization, moratorium and similar laws of general applicability relating to or affecting creditors’ rights and to general equity principles); (vi) neither the execution and
delivery of this Agreement by such Covered Person nor the consummation of the transactions contemplated herein conflicts with or results in a breach of any of the terms, conditions or provisions of any agreement or instrument to which such Covered
Person is a party or by which the material assets of such Covered Person are bound (including the organizational documents of such Covered Person, if such Covered Person is other than a natural person), or constitutes a default under any of the
foregoing, or violates any law or regulation; (vii) such Covered Person has obtained all authorizations, consents, approvals and clearances of all courts, governmental agencies and authorities, and any other person, if any (including the spouse
of such Covered Person with respect to the interest of such spouse in the Covered Interests or Registrable Securities of such Covered Person if the consent of such spouse is required), required to permit such Covered Person to enter into this
Agreement and to consummate the transactions contemplated herein; (viii) there are no actions, suits or proceedings pending, or, to the knowledge of such Covered Person, threatened against or affecting such Covered Person or such Covered
Person’s assets in any court or before or by any federal, state, municipal or other governmental department, commission, board, bureau, agency or instrumentality which, if adversely determined, would impair the ability of such Covered Person to
perform this Agreement; (ix) the performance of this Agreement will not violate any order, writ, injunction, decree or demand of any court or federal, state, municipal or other governmental department, commission, board, bureau, agency or
instrumentality to which such Covered Person is subject; and (x) no statement, representation or warranty made by such Covered Person in this Agreement, nor any information provided by such Covered Person for inclusion in a report filed
pursuant to Section 4.5 hereof or in a registration statement filed by Lazard Ltd, contains or will contain any untrue statement of a material fact or omits or will omit to state a material fact necessary in order to make the statements,
representations or warranties contained herein or information provided therein not misleading. 
 Each Covered Person shall promptly notify
LAZ-MD and Lazard Ltd of any breaches of such representations or covenants. 
 ARTICLE III 
 VOTING AGREEMENT 
 Section 3.1
Preliminary Vote of Covered Persons. Prior to any vote of the stockholders of Lazard Ltd, there shall be a separate, preliminary vote, on each matter upon which a stockholder vote of Lazard Ltd is then proposed to be taken (each, a
“Preliminary Vote”), of the Covered Interests beneficially owned by the Covered Persons. The Preliminary Vote shall be conducted pursuant to procedures established by LAZ-MD, including meetings or by proxy or written instruction by
or of the Covered Persons. 
 Section 3.2 Voting of the Covered Interests. Each Covered Person shall be entitled to instruct LAZ-MD to
vote the Class B Common Stock in proportion to the number of votes represented by the shares of Common Stock into which such Covered Interests are then exchangeable under the terms of the Operating Agreement, the Lazard Group Operating Agreement and
the Master Separation Agreement on the matter in question by the Covered Interests in the Preliminary Vote, provided, however, that notwithstanding anything herein to the contrary the Board shall have the ability to vote the Class B
Common Stock in its discretion (including in a manner different than as instructed by the Covered Persons) if it determines in good faith that such action is in the best interests of LAZ-MD. In the event that a Covered Person fails to participate in
the Preliminary Vote, the votes of that Covered Person will be abstained and excluded from the vote for such matters. LAZ-MD shall be obligated (a) to attend as proxy, or cause a person designated by it and acting as lawful proxy to attend as
proxy, each meeting of the stockholders of Lazard Ltd and to vote or to cause such designee to vote the Class B Common Stock over which it has the power to vote in accordance with the results of the Preliminary Vote as set forth in this
Section 3.2, and (b) to develop procedures governing Preliminary Votes. 
  

 6 

 Section 3.3 Acknowledgements; Determinations. 
 (a) Each Covered Person acknowledges and agrees as follows: (i) in the event that any matters shall come before a meeting of
stockholders of Lazard Ltd, or of any class of stockholders of Lazard Ltd, or any adjournment or postponement thereof (including matters related to adjournment or postponement thereof), that were not voted upon in a Preliminary Vote, LAZ-MD may vote
on such matters as LAZ-MD sees fit in its sole discretion, (ii) LAZ-MD shall be the sole record holder and legal and beneficial owner of the Class B Common Stock and, notwithstanding anything herein to the contrary, this Agreement shall not
confer any right, title or interest in, to or under the Class B Common Stock to any Covered Person, and (iii) except as expressly provided in this Article III with respect to the voting of the Class B Common Stock, LAZ-MD shall have the right
to take all action, and exercise all rights, with respect to the Class B Common Stock in its sole discretion if it determines in good faith that such action is in the best interest of LAZ-MD, and, notwithstanding anything herein to the contrary, no
Covered Person shall, by virtue of being a party to this Agreement, have any right to direct LAZ-MD to exercise, or otherwise directly or indirectly exercise, any rights relating to the Class B Common Stock, whether arising under the Companies Act
1981 of Bermuda and Bye-Laws of Lazard Ltd or otherwise, including the right to nominate directors of Lazard Ltd, propose business for meetings of stockholders of Lazard Ltd or otherwise submit stockholder proposals, call any special meetings of
stockholders (or any class thereof) of Lazard Ltd, tender or otherwise transfer the Class B Common Stock or to take any other action in respect of the Class B Common Stock. 
 (b) Each Covered Person acknowledges and agrees that all determinations necessary or advisable under this Article III shall be made by the
Board, whose determinations shall be final and binding. The Board’s determinations and actions (including waivers) under this Article III need not be uniform and may be made selectively among Covered Persons that are not similarly situated.

 (c) The provisions of Section 9.1 of the Operating Agreement of LAZ-MD are hereby incorporated by reference into this
Agreement. Without limiting the foregoing, each Covered Person acknowledges and agrees that the members of the Board in acting under this Agreement shall at all times be acting in their individual capacities and not as directors or officers of
LAZ-MD, Lazard Group or Lazard Ltd and, to the fullest extent permitted by law, in so acting or failing to act under this Agreement shall not have any fiduciary duties to the Covered Persons as a member of the Board by virtue of the fact that one or
more of such members may also be serving as a director or officer of LAZ-MD, Lazard Group, Lazard Ltd or otherwise. 
 Section 3.4 Voting
Related Expenses. LAZ-MD shall be responsible for all expenses of LAZ-MD and the Board incurred in the operation and administration of Article III, including expenses of proxy solicitation for and tabulation of the Preliminary Vote, expenses
incurred in preparing appropriate filings of LAZ-MD and correspondence with the SEC, lawyers’, accountants’, agents’, consultants’, experts’, investment banking and other professionals’ fees, expenses incurred in
enforcing the provisions of this Agreement and expenses incurred in maintaining any necessary or appropriate books and records relating to this Agreement. 
 Section 3.5 Governmental Authorities. LAZ-MD acknowledges that it is solely responsible for any Filings arising solely as a result of its holdings of capital stock of Lazard Ltd. Each Covered Person hereby
acknowledges and agrees that, unless otherwise directed by LAZ-MD or Lazard Ltd in writing, such Covered Person shall be solely responsible for making, and shall in a timely manner make, any and all reports, filings or other notifications with any
Governmental Authorities, including any reports of beneficial ownership on Schedule 13D or 13G under the Exchange Act, with respect to any rights or interests of such Covered Person under this Article III (each a “Filing”) and shall
be solely responsible for the cost and expense thereof. Such Covered Person understands and agrees that neither LAZ-MD nor Lazard Ltd has any related obligations relating to or responsibility for any such Filings. Such Covered Person shall cooperate
fully with the other Covered Persons to achieve the timely filing of any such Filings and any amendments thereto as may be required, and such Covered Person agrees that any information concerning such Covered Person which such Covered Person
furnishes in connection with the preparation and filing of any such Filing will be complete and accurate. No fewer than five business days prior to the submission of a Filing, each Covered Person submitting such Filing 

  

 7 

 
shall furnish to LAZ-MD and Lazard Ltd copies of such Filing as proposed to be filed. LAZ-MD and Lazard Ltd 
 shall each have the right to request that the filing Covered Person modify any information contained in such Filing or amendment or supplement thereto, and such Covered
Person shall use his reasonable best efforts to comply with such request; provided that compliance with such request shall not cause any Covered Person to violate applicable law or regulation. 
 Section 3.6 Adjustment upon Changes in Capitalization; Adjustments upon Changes of Control. In the event of any business combination,
restructuring, recapitalization or other extraordinary transaction involving LAZ-MD or Lazard Group as a result of which securities of a person other than LAZ-MD or Lazard Group that are exchangeable for Common Stock shall be issued or distributed
in exchange for or in replacement of Covered Interests, LAZ-MD and the Covered Persons agree that this Agreement shall also continue in full force and effect with respect to such securities of such other person, and the terms “Covered
Interests,” “Class II Interests,” “Lazard Group Common Interests,” “LAZ-MD” and “Lazard Group” shall refer to, as applicable, such securities and such person, respectively. If the Board deems it
desirable, any such adjustments may take effect from the record date or another appropriate date. In the event of any business combination, restructuring, recapitalization or other extraordinary transaction involving Lazard Ltd that affects the
capital stock of Lazard Ltd, the Board may, in its sole discretion, (a) terminate the provisions of this Article III or (b) adjust the voting structure set forth in this Article III as necessary to preserve the initial intent of such
provisions. 
 Section 3.7 Further Assurances. Each Covered Person agrees to execute such additional documents and take such further
action as may be reasonably necessary to effect the provisions of this Article III. 
 ARTICLE IV 
 REGISTRATION RIGHTS 
 Section 4.1
Annual Registration. 
 (a) With respect to each of the third through the ninth anniversaries of the IPO Date, Lazard
Ltd shall use its reasonable best efforts to effect the registration under the Securities Act of sales by Covered Persons of the following Registrable Securities: (i) all Registrable Securities issuable to Covered Persons in respect of the
exchange of Covered Interests in connection with such anniversary date pursuant to the Master Separation Agreement for such period (provided that such Covered Persons shall have complied with the notice provisions with respect thereto set forth in
the Master Separation Agreement) and (ii) all other Registrable Securities of any Covered Persons which Registrable Securities are reasonably expected to continue to be Registrable Securities at the expected filing date for the registration
statement with respect to such registration and which Covered Persons shall have provided Lazard Ltd with a written request for registration at least 20 business days prior to the applicable anniversary date requesting registration of such
Registrable Securities (each such registration, an “Annual Registration”); provided, however, that Lazard Ltd shall not be obligated to file any such registration statement or effect such registration if the amount of
all such Registrable Securities does not equal or exceed the Minimum Share Number (including, for purposes of calculating such Minimum Share Number, any Registrable Securities that are issuable pursuant to an MD Exchange in accordance with the terms
and subject to the conditions set forth in the Master Separation Agreement such that such Registrable Securities would be capable of being sold in such Annual Registration) as of the date of such filing or registration. Lazard Ltd shall use its
reasonable best efforts, subject to the restrictions in Section 4.1(d), to file a registration statement under the Securities Act with respect to each Annual Registration as promptly as reasonably practicable following the applicable Periodic
Filing Date. 
 (b) An Annual Registration may, at the option of Lazard Ltd, be conducted either as a Public Offering or as a
shelf registration; provided, however, that, if Lazard Ltd elects to conduct such offering as a shelf registration, the Board of Directors of LAZ-MD may request within five (5) days after notice thereof that such Annual Registration be
conducted as a Public Offering, in which case Lazard Ltd shall conduct such 

  

 8 

 
Annual Registration as a Public Offering. If an Annual Registration prior to the seventh anniversary of the 
 IPO Date involves a Public Offering and the managing underwriter advises Lazard Ltd that, in its view, the number of shares of Common Stock required to be
included in such Public Offering would adversely impact offering or the market for the Common Stock, Lazard Ltd may in its discretion reduce the number of shares of Common Stock included in such Public Offering, provided that Lazard Ltd shall
consult with the Board of Directors of LAZ-MD with respect to such reduction (and shall use reasonable efforts to so consult prior to such reduction). If an Annual Registration on or after the seventh anniversary of the IPO Date involves a Public
Offering and the managing underwriter advises Lazard Ltd that, in its view, the number of shares of Common Stock requested to be included in such Public Offering exceeds the largest number of shares that can be sold within the price range (or 10%
below the end of such range) that was included in the “red herring” registration statement for such Public Offering (provided that the Board of Directors of LAZ-MD shall not have objected to such price range prior to the filing of such red
herring registration statement after notice thereof), the number of shares of Common Stock included in such Public Offering shall be reduced to such largest number of shares. In the event that the number of shares of Common Stock requested to be
included in such Public Offering is reduced in accordance with this Section 4.1(b), Lazard Ltd shall include in such Public Offering, in the priority listed below, up to the applicable maximum number of shares to be included in such Public
Offering as determined in the immediately preceding two sentences: 
 (i) first, all Registrable Securities that are requested
to be registered in the Annual Registration by any Covered Persons and were issued or are issuable in respect of MD Exchangeable Interests that, pursuant to the Master Separation Agreement, first became capable of being exchanged pursuant to an MD
Exchange on or prior to the third anniversary of the IPO Date (allocated, if necessary for the offering not to exceed the Maximum Offering Size, pro rata among such Covered Persons on the basis of the relative number of shares of such Registrable
Securities so requested to be included in such registration by each such Covered Person); 
 (ii) second, all Registrable
Securities that are requested to be registered in the Annual Registration by any Covered Persons and were issued or are issuable in respect of MD Exchangeable Interests that, pursuant to the Master Separation Agreement, first became capable of being
exchanged pursuant to an MD Exchange on or prior to the fourth anniversary (but after the third anniversary) of the IPO Date (allocated, if necessary for the offering not to exceed the Maximum Offering Size, pro rata among such Covered Persons on
the basis of the relative number of shares of such Registrable Securities so requested to be included in such registration by each such Covered Person); 
 (iii) third, all Registrable Securities that are requested to be registered in the Annual Registration by any Covered Persons and were issued or are issuable in respect of MD Exchangeable Interests that, pursuant to
the Master Separation Agreement, first became capable of being exchanged pursuant to an MD Exchange on or prior to the fifth anniversary (but after the fourth anniversary) of the IPO Date (allocated, if necessary for the offering not to exceed the
Maximum Offering Size, pro rata among such Covered Persons on the basis of the relative number of shares of such Registrable Securities so requested to be included in such registration by each such Covered Person); 
 (iv) fourth, all Registrable Securities that are requested to be registered in the Annual Registration by any Covered Persons and were
issued or are issuable in respect of MD Exchangeable Interests that, pursuant to the Master Separation Agreement, first became capable of being exchanged pursuant to an MD Exchange on or prior to the sixth anniversary (but after the fifth
anniversary) of the IPO Date (allocated, if necessary for the offering not to exceed the Maximum Offering Size, pro rata among such Covered Persons on the basis of the relative number of shares of such Registrable Securities so requested to be
included in such registration by each such Covered Person); and 
 (v) fifth, all Registrable Securities that are requested to
be registered in the Annual Registration by any Covered Persons and were issued or are issuable in respect of MD Exchangeable Interests that, pursuant to the Master Separation Agreement, first became capable of being exchanged pursuant to an MD
Exchange after the sixth anniversary of the IPO Date (allocated, if necessary for the offering not to 

  

 9 

 
exceed the Maximum Offering Size, pro rata among such Covered Persons on the basis of the relative 
 number of shares of such Registrable Securities so requested to be included in such registration by each such Covered Person) (the priority among Covered
Persons set forth in clauses (i)-(v) shall be referred to herein as the “Covered Persons Priority”). 
 In determining, for a Covered
Person, the number of such Covered Person’s MD Exchangeable Interests that first became capable of being exchanged pursuant to an MD Exchange in relation to a certain date (and the corresponding number of Registrable Securities issued or
issuable in respect of such MD Exchangeable Interests), any exchanges of such Covered Person’s MD Exchangeable Interests for shares of Common Stock prior to the relevant date of determination shall be deemed to reduce, first, the number of such
Covered Person’s MD Exchangeable Interests that first became capable of being exchanged and, thereafter, the number of such Covered Person’s MD Exchangeable Interests that next became capable of being exchanged (until each such group shall
be exhausted). 
 (c) Lazard Group shall be liable for and pay all Registration Expenses in connection with any Annual
Registration, regardless of whether such Registration is effected. Lazard Ltd shall have the right (but not the obligation) to register additional shares of Common Stock and other securities together with such Annual Registration, provided that such
shares shall be included in such registration in a priority after the shares included in the Covered Persons Priority. 
 (d)
Upon notice to each Covered Person participating in the applicable Annual Registration, Lazard Ltd may postpone effecting a registration pursuant to this Section 4.1 on one occasion during any period of six consecutive months for a reasonable
time specified in the notice but not exceeding 120 days (which period may not be extended or renewed), if (i) Lazard Ltd shall determine in good faith that effecting the registration would materially and adversely affect an offering of
securities of such company the preparation of which had then been commenced or (ii) Lazard Ltd is in possession of material non-public information the disclosure of which during the period specified in such notice Lazard Ltd believes in good
faith would not be in the best interests of Lazard Ltd. 
 Section 4.2 Demand Registration. 
 (a) If at any time following the third anniversary of the IPO Date, Lazard Ltd shall receive a written request (a “Demand
Notice”) from a Covered Person or group of Covered Persons (a “Demand Requesting Covered Person”) that Lazard Ltd effect the registration under the Securities Act of all or any portion of such Covered Person’s
Registrable Securities (including any Registrable Securities that are issuable pursuant to an MD Exchange in accordance with the terms and subject to the conditions set forth in the Master Separation Agreement such that such Registrable Securities
would be capable of being sold in such Demand Registration) representing Registrable Securities requested to be included in such registration equal to or in excess of the Minimum Demand Number (including, for purposes of calculating the Minimum
Demand Number, any Registrable Securities that are issuable pursuant to an MD Exchange in accordance with the terms and subject to the conditions set forth in the Master Separation Agreement such that such Registrable Securities would be capable of
being sold in such Demand Registration) as of the date on which the Demand Registration is made (a “Demand Registration”), specifying the intended method of disposition thereof, then Lazard Ltd shall use its reasonable best efforts
to effect, as expeditiously as reasonably practicable, subject to the restrictions in Section 4.2(d) and Section 4.3 and such Demand Requesting Covered Person’s compliance with its obligations under the other applicable provisions of
this Article IV, the registration under the Securities Act of the Registrable Securities for which such Demand Requesting Covered Person has requested registration under this Section 4.2, all to the extent necessary to permit the disposition
(in accordance with the intended methods thereof as aforesaid) of the Registrable Securities so to be registered. Upon the receipt of a Demand Notice, Lazard Ltd shall promptly give written notice to all other holders of Registrable Securities that
such Demand Registration is to be effected. Lazard Ltd shall include in such Demand Registration such Registrable Securities for which it has received written requests by such other holders within fifteen (15) days after the delivery of the
written notice to such other holders, 

  

 10 

 
and such other holders that submit such written requests for inclusion in the Demand Registration within such fifteen (15) day period shall be deemed to
be included in the definition of “Demand Requesting Covered Person” (provided that, for the avoidance of doubt, the Registrable Securities of such other holders shall not be included in the calculation of Minimum Demand Number with respect
to such Demand Registration). Notwithstanding the foregoing, any Demand Notice submitted during any “blackout” period of Lazard Ltd applicable to its directors and executive officers shall not be deemed to have been delivered until the
first Business Day following the earlier to occur of the expiration of (x) such periods and (y) thirty (30) days following the beginning of any such period (and this restriction on submission of Demand Notices shall not be effective
for more than thirty (30) days in any ninety (90) day period). 
 (b) At any time prior to the effective date of the
registration statement relating to such registration, the Demand Requesting Covered Person may revoke such Demand Registration request by providing a notice to Lazard Ltd revoking such request. Lazard Group shall be liable for and pay all
Registration Expenses in connection with any Demand Registration. Notwithstanding any other provisions of this Agreement to the contrary, (i) a Demand Requesting Covered Person shall be entitled to no more than one Demand Registration during
any six-month period, and (ii) Lazard Ltd shall not be obligated to seek to declare or make effective any registration statement with respect to a Demand Registration in the event that an Annual Registration or Piggyback Registration (as
defined below) had been available under this Article IV within the 180 days preceding the date of the Demand Notice; provided, that neither of the restrictions set forth in clauses (i) and (ii) shall restrict any Covered Person from
submitting a Demand Notice requesting a Demand Registration that complies with the other provisions of this Section 4.2 and the time period limitations set forth in clauses (i) and (ii) of this sentence. 
 (c) A Demand Registration may, at the option of Lazard Ltd, be conducted either as a Public Offering or as a shelf registration; provided,
however, that in the event that (1) any Registrable Shares that first became eligible for participation in an Annual Registration at the most recent Annual Registration hereunder and were sought to be so registered and sold in such Annual
Registration but were reduced as a result of the Maximum Offering Size in accordance with Section 4.1(b) shall continue to be unsold at such time (taking into account any prior Demand Registrations and Piggyback Registrations) and (2) the
Board of Directors of LAZ-MD shall object to Lazard Ltd’s election of a Public Offering, Lazard Ltd shall conduct such Demand Registration as a shelf registration. Lazard Ltd shall have the right (but not the obligation) to register additional
shares of Common Stock and other securities together with such Demand Registration. If a Demand Registration prior to the seventh anniversary of the IPO Date involves a Public Offering and the managing underwriter advises Lazard Ltd that, in its
view, the number of shares of Common Stock required to be included in such Public Offering would adversely impact the offering or the market for the Common Stock, Lazard Ltd may in its discretion reduce the number of shares of Common Stock included
in such Public Offering, provided that Lazard Ltd shall consult with the Board of Directors of LAZ-MD with respect to such reduction (and shall use reasonable efforts to so consult prior to such reduction). If a Demand Registration on or after the
seventh anniversary of the IPO Date involves a Public Offering and the managing underwriter advises Lazard Ltd that, in its view, the number of shares of Common Stock requested to be included in such Public Offering exceeds the largest number of
shares that can be sold within the price range (or 10% below the end of such range) that was included in the “red herring” registration statement for such Public Offering (provided that the Board of Directors of LAZ-MD shall not have
objected to such price range prior to the filing of such red herring registration statement after notice thereof), the number of shares of Common Stock included in such Public Offering shall be reduced to such largest number of shares. In the event
that the number of shares of Common Stock requested to be included in such Public Offering is reduced in accordance with this Section 4.2(c), Lazard Ltd shall include in such Public Offering, in the priority listed below, up to the applicable
maximum number of shares to be included in such Public Offering as determined in the immediately preceding two sentences: 
 (i) first, all Registrable Securities requested to be registered in the Demand Registration by the Demand Requesting Covered Persons according to the Covered Persons Priority; and 
  

 11 

 (ii) second, any securities proposed to be registered by Lazard Ltd or any securities
proposed to be registered for the account of any other persons (including under Section 4.3), with such priorities among them as Lazard Ltd shall determine or as is otherwise required by Section 4.3. 
 (d) Upon notice to the Demand Requesting Covered Person, Lazard Ltd may postpone effecting a registration pursuant to this
Section 4.1 on one occasion during any period of six consecutive months for a reasonable time specified in the notice but not exceeding 120 days (which period may not be extended or renewed), if (i) Lazard Ltd shall determine in good faith
that effecting the registration would materially and adversely affect an offering of securities of such company the preparation of which had then been commenced, (ii) Lazard Ltd is in possession of material non-public information the disclosure
of which during the period specified in such notice Lazard Ltd believes in good faith would not be in the best interests of Lazard Ltd, or (iii) an Annual Registration shall have commenced (or is reasonably expected to commence within 30 days
of such Demand Registration) (it being understood that, in lieu of any such Demand Registration, Lazard Ltd may elect to include any Demand Requesting Covered Person’s Registrable Securities subject to a Demand Registration hereunder with such
Annual Registration in full satisfaction of its obligations under this Section 4.2 with respect to such Demand Registration). 
 Section
4.3 Piggyback Registration. 
 (a) Subject to any contractual obligations to the contrary, if Lazard Ltd proposes to
register any of the equity securities issued by it under the Securities Act (other than a registration on Form S-8 or S-4, or any successor forms, relating to shares of Common Stock issuable upon exercise of employee stock options or in connection
with any employee benefit or similar plan of Lazard Ltd or in connection with a direct or indirect acquisition by Lazard Ltd of another Person or as a recapitalization or reclassification of securities of Lazard Ltd), whether or not for sale for its
own account, Lazard Ltd shall each such time give prompt notice at least five (5) business days prior to the anticipated filing date of the registration statement relating to such registration to each Covered Person holding Registrable
Securities, which notice shall set forth such Covered Person’s rights under this Section 4.3 and shall offer such Covered Person the opportunity to include in such registration statement the number of Registrable Securities of the same
class or series as those proposed to be registered as such Covered Person may request (a “Piggyback Registration”), subject to the provisions of Section 4.3(b) and such Covered Person’s compliance with its obligations
under the other applicable provisions of this Article IV. Upon the request of such Covered Person made within three (3) business days after the receipt of notice from Lazard Ltd (which request shall specify the number of Registrable Securities
intended to be registered by such Covered Person), Lazard Ltd shall use its reasonable best efforts to effect the registration under the Securities Act of all Registrable Securities that Lazard Ltd has been so requested to register by all such other
Covered Persons, to the extent necessary to permit the disposition of the Registrable Securities so to be registered, provided that (i) if such registration involves an underwritten Public Offering, all such Covered Persons requesting to
be included in Lazard Ltd’s registration must sell their Registrable Securities to the underwriters selected by Lazard Ltd on the same terms and conditions as apply to Lazard Ltd or the Requesting Covered Persons, as applicable, and
(ii) if, at any time after giving notice of its intention to register any securities pursuant to this Section 4.3(a) and prior to the effective date of the registration statement filed in connection with such registration, Lazard Ltd shall
determine for any reason not to register such securities, Lazard Ltd shall give notice to all such Covered Persons and, thereupon, shall be relieved of its obligation to register any Registrable Securities in connection with such registration. No
registration effected under this Section 4.3 shall relieve Lazard Ltd of its obligations to effect an Annual Registration or Demand Registration to the extent required by Section 4.1 or Section 4.2, respectively. Lazard Group shall
pay all Registration Expenses in connection with each Piggyback Registration. 
 (b) If a Piggyback Registration prior to the
seventh anniversary of the IPO Date involves a Public Offering and the managing underwriter advises Lazard Ltd that, in its view, the number of shares of Common Stock required to be included in such Public Offering would adversely impact the
offering or the 

  

 12 

 
market for the Common Stock, Lazard Ltd may in its discretion reduce the number of shares of Common Stock included in such Public Offering (subject to any
other contractual obligations to the contrary), provided that Lazard Ltd shall consult with the Board of Directors of LAZ-MD with respect to such reduction (and shall use reasonable efforts to so consult prior to such reduction). If a Piggyback
Registration on or after the seventh anniversary of the IPO Date involves a Public Offering and the managing underwriter advises Lazard Ltd that, in its view, the number of shares of Common Stock requested to be included in such Public Offering
exceeds the largest number of shares that can be sold within the price range (or 10% below the end of such range) that was included in the “red herring” registration statement for such Public Offering (provided that the Board of Directors
of LAZ-MD shall not have objected to such price range prior to the filing of such red herring registration statement after notice thereof), the number of shares of Common Stock included in such Public Offering shall be reduced to such largest number
of shares (subject to any other contractual obligations to the contrary). Subject to any other contractual obligations to the contrary, in the event that the number of shares of Common Stock requested to be included in such Public Offering is
reduced in accordance with this Section 4.3(b), Lazard Ltd shall include in such Public Offering, in the priority listed below, up to the applicable maximum number of shares to be included in such Public Offering as determined in the
immediately preceding two sentences: 
 (i) first, so much of Lazard Ltd securities proposed to be registered for the account
of Lazard Ltd and pursuant to any demand registration rights of third parties (in such priority between the two as Lazard Ltd may determine); 
 (ii) second, all Registrable Securities requested to be included in such registration by any Covered Persons according to the Covered Persons Priority; and 
 (iii) third, any securities proposed to be registered for the account of any other Persons with such priorities among them as Lazard Ltd
shall determine. 
 Section 4.4 Lock-Up Agreements. If any registration of Registrable Securities shall be effected in connection with
a Public Offering, no Covered Person shall effect any public sale or distribution, including any sale pursuant to Rule 144, of any shares of Common Stock or other security of Lazard Ltd (except as part of such Public Offering) during the period
beginning 14 days prior to the effective date of the applicable registration statement until the earlier of (i) such time as Lazard Ltd and the lead managing underwriter shall agree and (ii) 180 days (such period, the “Lock-Up
Period” for the applicable registration statement) (it being understood that such Covered Person shall have been provided the opportunity to participate in such Public Offering in accordance with this Article IV). 
 Section 4.5 Registration Procedures. Whenever a Covered Person requests that any Registrable Securities be registered pursuant to Section 4.2
or 4.3 or in respect of any Annual Registration pursuant to Section 4.1, subject to the provisions of such Sections, Lazard Ltd shall use its reasonable best efforts to effect the registration and the sale of such Registrable Securities in
accordance with the intended method of disposition thereof as promptly as practicable, and, in connection with any such request: 
 (a) Lazard Ltd shall as expeditiously as reasonably practicable prepare and file with the SEC and the Registrar of Companies in Bermuda a registration statement on any form for which Lazard Ltd then qualifies or that counsel for Lazard Ltd
shall deem appropriate and which form shall be available for the sale of the Registrable Securities to be registered thereunder in accordance with the intended method of distribution thereof, and use its reasonable best efforts to cause such filed
registration statement to become and remain effective for a period of not less than 40 days or, in the case of a shelf registration statement, 60 days (provided that any day during which a Lock-Up Period is in effect shall not constitute a day with
respect to such 60 day period) (or such shorter period in which all of the Registrable Securities of the Registering Covered Persons included in such registration statement shall have actually been sold thereunder). 
  

 13 

 (b) Prior to filing a registration statement or prospectus or any amendment or supplement
thereto, Lazard Ltd shall, if requested, furnish to each participating Covered Person and each underwriter, if any, of the Registrable Securities covered by such registration statement copies of such registration statement as proposed to be filed,
and thereafter Lazard Ltd shall furnish to such Covered Person and underwriter, if any, such number of copies of such registration statement, each amendment and supplement thereto (in each case including all exhibits thereto and documents
incorporated by reference therein), the prospectus included in such registration statement (including each preliminary prospectus and any summary prospectus) and any other prospectus filed under Rule 424 or Rule 430A under the Securities Act and
such other documents as such Covered Person or underwriter may reasonably request in order to facilitate the disposition of the Registrable Securities owned by such Covered Person. The Covered Person shall have the right to request that Lazard Ltd
modify any information contained in such registration statement, amendment and supplement thereto pertaining to such Covered Person and Lazard Ltd shall use its reasonable best efforts to comply with such request, provided, however,
that Lazard Ltd shall not have any obligation so to modify any information if Lazard Ltd reasonably expects that so doing would cause the prospectus to contain an untrue statement of a material fact or omit to state any material fact required to be
stated therein or necessary to make the statements therein not misleading. 
 (c) After the filing of the registration
statement, Lazard Ltd shall (i) cause the related prospectus to be supplemented by any required prospectus supplement, and, as so supplemented, to be filed pursuant to Rule 424 under the Securities Act and the Companies Act 1981 of Bermuda,
(ii) comply with the provisions of the Securities Act with respect to the disposition of all Registrable Securities covered by such registration statement during the applicable period in accordance with the intended methods of disposition by
the Registering Covered Persons thereof set forth in such registration statement or supplement to such prospectus and (iii) promptly notify each Registering Covered Person holding Registrable Securities covered by such registration statement of
any stop order issued or threatened by the SEC or any state securities commission and take all reasonable best efforts to prevent the entry of such stop order or to remove it if entered. 
 (d) Lazard Ltd shall use its reasonable best efforts to (i) register or qualify the Registrable Securities covered by such
registration statement under such other securities or “blue sky” laws of such jurisdictions in the United States as any Registering Covered Person holding such Registrable Securities reasonably (in light of such Covered Person’s
intended plan of distribution) requests, (ii) cause such Registrable Securities to be registered with or approved by such other governmental agencies or authorities as may be necessary by virtue of the business and operations of Lazard Ltd, and
(iii) do any and all other acts and things that may be reasonably necessary or advisable to enable such Covered Person to consummate the disposition of the Registrable Securities owned by such Covered Person, provided that Lazard Ltd
shall not be required to (A) qualify generally to do business in any jurisdiction where it would not otherwise be required to qualify but for this Section 4.5(d), (B) subject itself to taxation in any such jurisdiction or
(C) consent to general service of process in any such jurisdiction. 
 (e) Lazard Ltd shall immediately notify each
Registering Covered Person holding such Registrable Securities covered by such registration statement, at any time when a prospectus relating thereto is required to be delivered under the Securities Act, of the occurrence of an event requiring the
preparation of a supplement or amendment to such prospectus so that, as thereafter delivered to the purchasers of such Registrable Securities, such prospectus will not contain an untrue statement of a material fact or omit to state any material fact
required to be stated therein or necessary to make the statements therein not misleading and promptly prepare and make available to each such Covered Person and file with the SEC and the Registrar of Companies in Bermuda any such supplement or
amendment. 
  

 14 

 (f) Lazard Ltd shall select an underwriter or underwriters in connection with any Public
Offering and shall consult with the Board of Directors of LAZ-MD with respect to such selection (and shall use reasonable efforts to so consult prior to such selection). In connection with any Public Offering, Lazard Ltd shall enter into customary
agreements (including an underwriting agreement in customary form) and take such all other actions as are reasonably required in order to expedite or facilitate the disposition of such Registrable Securities in any such Public Offering, including
the engagement of a “qualified independent underwriter” in connection with the qualification of the underwriting arrangements with the National Association of Securities Dealers. 
 (g) Subject to execution of confidentiality agreements satisfactory in form and substance to Lazard Ltd in the exercise of its good faith
judgment, Lazard Ltd will give to each Registering Covered Person, its counsel and accountants (i) reasonable and customary access to its books and records and (ii) such opportunities to discuss the business of Lazard Ltd with its
directors, officers, employees, counsel and the independent public accountants who have certified its financial statements, as shall be appropriate, in the reasonable judgment of counsel, to such Registering Covered Person, to enable them to
exercise their due diligence responsibility. 
 (h) Lazard Ltd shall use its reasonable best efforts to furnish to each
Registering Covered Person and to each such underwriter, if any, a signed counterpart, addressed to such Covered Person or underwriter, of (i) any opinion or opinions of counsel to Lazard Ltd and (ii) any comfort letter or comfort letters
from Lazard Ltd’s independent public accountants, each in customary form and covering such matters of the kind customarily covered by opinions or comfort letters and in each case if and to the extent such opinion or comfort letter shall be
furnished to Lazard Ltd in connection therewith, as the case may be, if such Registering Covered Persons who collectively represent a majority of the Registrable Securities being sold in such registration so reasonably request. 
 (i) Each such Covered Person registering securities under this Article IV shall promptly furnish in writing to Lazard Ltd such information
regarding the distribution of the Registrable Securities as Lazard Ltd may from time to time reasonably request and such other information as may be legally required or advisable in connection with such registration. Lazard Ltd shall have the right
to require that sales or other dispositions in connection with any registration hereunder are subject to reasonable limitations or restrictions on size and manner of sale for the purpose of maintaining an orderly market for the Common Stock.

 (j) The Covered Person agrees that, upon receipt of any notice from Lazard Ltd of the happening of any event of the kind
described in Section 4.5(e), such Covered Person shall forthwith discontinue disposition of Registrable Securities pursuant to the registration statement covering such Registrable Securities until such Covered Person’s receipt of the
copies of the supplemented or amended prospectus contemplated by Section 4.5(e), and, if so directed by Lazard Ltd, such Covered Person shall deliver to Lazard Ltd all copies, other than any permanent file copies then in such Covered
Person’s possession, of the most recent prospectus covering such Registrable Securities at the time of receipt of such notice. If Lazard Ltd shall give such notice, Lazard Ltd shall extend the period during which such registration statement
shall be maintained effective (including the period referred to in Section 4.5(a)) by the number of days during the period from and including the date of the giving of notice pursuant to Section 4.5(e) to the date when Lazard Ltd shall
make available to such Covered Person a prospectus supplemented or amended to conform with the requirements of Section 4.5(e). 
 (k) Lazard Ltd shall use its reasonable efforts to list all Registrable Securities covered by such registration statement on any securities exchange or quotation system on which any of the Registrable Securities are then listed or traded.

 (l) Lazard Ltd shall have appropriate officers of Lazard Ltd (i) prepare and make presentations at any “road
shows” and before analysts and rating agencies, as the case may be, (ii) take other actions to obtain ratings for any Registrable Securities, if applicable, and (iii) otherwise use their reasonable best efforts to cooperate in the
offering, marketing or selling of the Registrable Securities, in each case as reasonably requested by the underwriters in connection with any Public Offering hereunder. 
  

 15 

 Section 4.6 Indemnification by Lazard Ltd. Lazard Ltd agrees to indemnify and hold harmless the
Registering Covered Person holding Registrable Securities covered by a registration statement, its officers, directors, employees, partners and agents, and each Person, if any, who controls such Covered Person within the meaning of Section 15
of the Securities Act or Section 20 of the Exchange Act from and against any and all losses, claims, damages, liabilities and expenses (including reasonable expenses of investigation and reasonable attorneys’ fees and expenses)
(“Damages”) caused by or relating to any untrue statement or alleged untrue statement of a material fact contained in any registration statement or prospectus relating to the Registrable Securities (as amended or supplemented if
Lazard Ltd shall have furnished any amendments or supplements thereto) or any preliminary prospectus, or caused by or relating to any omission or alleged omission to state therein a material fact required to be stated therein or necessary to make
the statements therein not misleading, except insofar as such Damages are caused by or related to any such untrue statement or omission or alleged untrue statement or omission so made based upon information furnished in writing to Lazard Ltd by such
Covered Person or on such Covered Person’s behalf (in each case, in such person’s capacity as a Covered Person) expressly for use therein; provided that, with respect to any untrue statement or omission or alleged untrue statement
or omission made in any preliminary prospectus, or in any prospectus, as the case may be, the indemnity agreement contained in this paragraph shall not apply to the extent that any Damages result from the fact that a current copy of the prospectus
(or such amended or supplemented prospectus, as the case may be) was not sent or given to the Person asserting any such Damages at or prior to the written confirmation of the sale of the Registrable Securities to such Person if it is determined that
Lazard Ltd provided such prospectus to such Covered Person and it was the responsibility of such Covered Person to provide such Person with a current copy of the prospectus (or such amended or supplemented prospectus, as the case may be) and such
current copy of the prospectus (or such amended or supplemented prospectus, as the case may be) would have cured the defect giving rise to such Damages. 
 Section 4.7 Indemnification by Participating Covered Persons. Each Covered Person who holds Registrable Securities covered by any registration statement agrees to indemnify and hold harmless Lazard Ltd, its
affiliates and their respective officers, directors and agents and each Person, if any, who controls Lazard Ltd within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act to the same extent as the
foregoing indemnity from Lazard Ltd to such Covered Person, but only (i) with respect to information furnished in writing by such Covered Person or on such Covered Person’s behalf (in each case, in such person’s capacity as a Covered
Person) expressly for use in any registration statement or prospectus relating to the Registrable Securities, or any amendment or supplement thereto, or any preliminary prospectus or (ii) to the extent that any Damages result from the fact that
a current copy of the prospectus (or such amended or supplemented prospectus, as the case may be) was not sent or given to the Person asserting any such Damages at or prior to the written confirmation of the sale of the Registrable Securities
concerned to such Person if it is determined that it was the responsibility of such Covered Person to provide such Person with a current copy of the prospectus (or such amended or supplemented prospectus, as the case may be) and such current copy of
the prospectus (or such amended or supplemented prospectus, as the case may be) would have cured the defect giving rise to such loss, claim, damage, liability or expense. The Covered Person also agrees to indemnify and hold harmless underwriters of
the Registrable Securities, their officers and directors and each Person who controls such underwriters within the meaning of either Section 15 of the Securities Act or Section 20 of the Exchange Act on substantially the same basis as that
of the indemnification of Lazard Ltd provided in this Section 4.5. As a condition to including Registrable Securities in any registration statement filed in accordance with Article IV, Lazard Ltd may require that it shall have received an
undertaking reasonably satisfactory to it from any underwriter to indemnify and hold it harmless to the extent customarily provided by underwriters with respect to similar securities. No Registering Covered Person shall be liable under this
Section 4.7 for any Damages in excess of the net proceeds realized by such Covered Person in the sale of Registrable Securities of such Covered Person to which such Damages relate. 
 Section 4.8 Conduct of Indemnification Proceedings. If any proceeding (including any governmental investigation) shall be instituted involving any
Person in respect of which indemnity may be sought pursuant to this Article IV, such Person (an “Indemnified Party”) shall promptly notify the Person against whom such 

  

 16 

 
indemnity may be sought (the “Indemnifying Party”) in writing and the Indemnifying Party shall have the right to assume the defense thereof,
including the employment of counsel reasonably satisfactory to such Indemnified Party, and shall assume the payment of all fees and expenses, provided that the failure of any Indemnified Party so to notify the Indemnifying Party shall not
relieve the Indemnifying Party of its obligations hereunder except to the extent that the Indemnifying Party is materially prejudiced by such failure to notify. In any such proceeding, any Indemnified Party shall have the right to retain its own
counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified Party unless (i) the Indemnifying Party and the Indemnified Party shall have mutually agreed to the retention of such counsel or (ii) in the
reasonable judgment of such Indemnified Party and in the opinion of counsel to such Indemnified Party, representation of both parties by the same counsel would be inappropriate due to actual or potential differing interests between them. It is
understood that, in connection with any proceeding or related proceedings in the same jurisdiction, the Indemnifying Party shall not be liable for the reasonable fees and expenses of more than one separate firm of attorneys (in addition to any local
counsel) at any time for all such Indemnified Parties, and that all such fees and expenses shall be reimbursed as they are incurred. In the case of any such separate firm for the Indemnified Parties, such firm shall be designated in writing by the
Indemnified Parties. The Indemnifying Party shall not be liable for any settlement of any proceeding effected without its written consent, but if settled with such consent, or if there be a final judgment for the plaintiff, the Indemnifying Party
shall indemnify and hold harmless such Indemnified Parties from and against any loss or liability (to the extent stated above) by reason of such settlement or judgment. Without the prior written consent of the Indemnified Party, no Indemnifying
Party shall effect any settlement of any pending or threatened proceeding in respect of which any Indemnified Party is or could have been a party and indemnity could have been sought hereunder by such Indemnified Party, unless such settlement
includes an unconditional release of such Indemnified Party from all liability arising out of such proceeding. 
 Section 4.9
Contribution. If the indemnification provided for in this Article VI is unavailable to the Indemnified Parties in respect of any Damages, then each such Indemnifying Party, in lieu of indemnifying such Indemnified Party, shall contribute to
the amount paid or payable by such Indemnified Party as a result of such Damages (i) as between Lazard Ltd and the Registering Covered Person holding Registrable Securities covered by a registration statement on the one hand and the
underwriters on the other, in such proportion as is appropriate to reflect the relative benefits received by Lazard Ltd and such Covered Person on the one hand and the underwriters on the other, from the offering of the Registrable Securities, or if
such allocation is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits but also the relative fault of Lazard Ltd and such Covered Person on the one hand and of such underwriters on the
other in connection with the statements or omissions that resulted in such Damages, as well as any other relevant equitable considerations and (ii) as between Lazard Ltd on the one hand and such Covered Person on the other, in such proportion
as is appropriate to reflect the relative fault of Lazard Ltd and of such Covered Person in connection with such statements or omissions, as well as any other relevant equitable considerations. The relative benefits received by Lazard Ltd and such
Covered Person, on the one hand, and such underwriters, on the other hand, shall be deemed to be in the same proportion as the total proceeds from the offering (net of underwriting discounts and commissions but before deducting expenses) received by
Lazard Ltd and such Covered Person bear to the total underwriting discounts and commissions received by such underwriters, in each case as set forth in the table on the cover page of the prospectus. The relative fault of Lazard Ltd and such Covered
Person on the one hand and of such underwriters on the other shall be determined by reference to, among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact
relates to information supplied by Lazard Ltd and such Covered Person or by such underwriters. The relative fault of Lazard Ltd on the one hand and of such Covered Person on the other shall be determined by reference to, among other things, whether
the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material fact relates to information supplied by such party, and the parties’ relative intent, knowledge, access to information and
opportunity to correct or prevent such statement or omission. 
 Lazard Ltd and the Covered Person agree that it would not be just and
equitable if contribution pursuant to this Section 4.9 were determined by pro rata allocation (even if the underwriters were treated as one entity for such purpose) or by any other method of allocation that does not take account of the
equitable considerations 

  

 17 

 
referred to in the immediately preceding paragraph. The amount paid or payable by an Indemnified Party as a result of the Damages referred to in the
immediately preceding paragraph shall be deemed to include, subject to the limitations set forth above, any legal or other expenses reasonably incurred by such Indemnified Party in connection with investigating or defending any such action or claim.
Notwithstanding the provisions of this Section 4.9, no underwriter shall be required to contribute any amount in excess of the amount by which the total price at which the Registrable Securities underwritten by it and distributed to the public
were offered to the public exceeds the amount of any Damages that such underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission, and no Registering Covered Person shall be
required to contribute any amount in excess of the amount by which the total price at which the Registrable Securities of such Covered Person were offered to the public (less underwriters’ discounts and commissions) exceeds the amount of any
Damages that such Covered Person has otherwise been required to pay by reason of such untrue or alleged untrue statement or omission or alleged omission. No Person guilty of fraudulent misrepresentation (within the meaning of Section 11(f) of
the Securities Act) shall be entitled to contribution from any Person who was not guilty of such fraudulent misrepresentation. 
 Section
4.10 Participation in Public Offering. No Covered Person may participate in any Public Offering hereunder unless such Covered Person (a) agrees to sell such Covered Person’s securities on the basis provided in any underwriting
arrangements approved by the Covered Persons entitled hereunder to approve such arrangements and (b) completes and executes all questionnaires, powers of attorney, indemnities, underwriting agreements and other documents reasonably required
under the terms of such underwriting arrangements and the provisions of this Agreement in respect of registration rights. 
 Section 4.11
Other Indemnification. Indemnification similar to that specified herein (with appropriate modifications) shall be given by Lazard Ltd and the Registering Covered Person participating therein with respect to any required registration or other
qualification of securities under any federal or state law or regulation or governmental authority other than the Securities Act. 
 Section
4.12 Cooperation by Lazard Ltd. If the Covered Person shall transfer any Registrable Securities pursuant to Rule 144, Lazard Ltd shall use its commercially reasonable efforts to cooperate with the Covered Person and shall provide to the
Covered Person such information as the Covered Person shall reasonably request. 
 Section 4.13 No Transfer of Registration Rights.
Except as set forth in Section 4.14, none of the rights of the Covered Person under this Article VI shall be assignable by any Covered Person to any person acquiring securities unless the person so acquiring such securities shall already be a
Covered Person. 
 Section 4.14 Parties in Interest. Each Covered Person shall be entitled to receive the benefits of this Agreement
and shall be bound by the terms and provisions of this Agreement by reason of such Covered Person’s election to participate in a registration under this Article IV. All of the terms and provisions of this Article IV shall be binding upon, shall
inure to the benefit of and shall be enforceable by the respective successors and permitted assigns of Lazard Ltd and any Covered Person with respect to registrations hereunder. Unless otherwise specified by Lazard Ltd in its sole discretion, any
transferee (including, without limitation, any charitable foundation or public charities) of any Covered Person permitted in accordance with the applicable (in the case of Covered Interests) limited liability company agreement and otherwise in
accordance with this Agreement that shall acquire Registrable Securities, in any manner, whether by gift, bequest, purchase, operation of law or otherwise, shall, without any further action of any kind, be entitled to receive the benefits of and be
conclusively deemed to have agreed to be bound by and to perform all of the terms and provisions of this Agreement to the aforesaid extent as if such person was a Covered Person hereunder with respect to the relevant registration. Lazard Ltd may,
however, as a condition thereto require any such transferee to be added to Appendix A hereto in accordance with Section 5.2(b) hereof or otherwise sign an agreement acknowledging that is bound by the terms and provisions of the Agreement as if
such transferee were a Covered Person with respect to the relevant registration. 
  

 18 

 Section 4.15 Acknowledgement Regarding Lazard Ltd. Any determination with respect to any Covered
Person’s compliance with the procedural requirements of Section 4.1, Section 4.2 and Section 4.3 shall be made by Lazard Ltd in its good faith judgment, the determination of which with respect to the foregoing shall be
final and binding. 
 Section 4.16 Mergers, Recapitalizations, Exchanges or Other Transactions Affecting Registrable Securities. The
provisions of this Agreement shall apply to the full extent set forth herein with respect to the Registrable Securities, to any and all securities or capital stock of LAZ-MD, Lazard Group or Lazard Ltd or any successor or assign of any such company
(whether by merger, amalgamation, consolidation, sale of assets or otherwise) that may be issued in respect of, in exchange for, or in substitution of such Registrable Securities, by reason of any dividend, split, issuance, reverse split,
combination, recapitalization, reclassification, merger, amalgamation, consolidation or otherwise. 
 ARTICLE V 
 MISCELLANEOUS 
 Section 5.1 Term of
the Agreement; Termination of Certain Provisions. 
 (a) The term of this Agreement shall begin immediately upon execution
hereof by each of Lazard Ltd and LAZ-MD and shall continue until the first to occur of (i) such time as no Covered Person holds any Covered Interests or Registrable Securities and (ii) such time as this Agreement is terminated by the
affirmative vote of Covered Persons that beneficially own not less than 66 2/3% of the outstanding Covered Interests (based on the number of units represented by such Covered Interests). Each of the Continuing Provisions and Section 4.6 shall
survive such expiration of the term of this Agreement. 
 (b) Unless this Agreement is theretofore terminated pursuant to
Section 5.1(a) hereof, a Covered Person shall be bound by the provisions of this Agreement with respect to any Covered Interest or Registrable Security until such time as such Covered Person ceases to hold any Covered Interest or Registrable
Security. Thereafter, such Covered Person shall no longer be bound by the provisions of this Agreement other than Sections 4.7, 4.8, 4.9 and 4.11 and Article V (the “Continuing Provisions”), and such Covered Person’s name shall
be removed from Appendix A to this Agreement. 
 (c) Each holder of a Class II Interest on the date hereof and any transferee
of a Covered Interest pursuant to, and in accordance with, a permitted transfer under the Operating Agreement or the Lazard Group Operating Agreement (each, a “Permitted Transferee”) shall be added to Appendix A as a Covered Person;
provided that such holder of a Class II Interest or Permitted Transferee, as applicable, shall first sign an agreement in the form approved by Lazard Ltd acknowledging that such holder of a Class II Interest or Permitted Transferee, as
applicable is bound by the terms and provisions of the Agreement. 
 Section 5.2 Amendments; Waiver. 
 (a) The provisions of this Agreement may be amended only by the affirmative vote of a majority of the outstanding Covered Interests and
the consent of Lazard Ltd and LAZ-MD; provided, that (i) any amendment to Section 5.1(a) and this clause 5.2(a)(i) shall require the affirmative approval of 66 2/3% of the outstanding Covered Interests (based on the number of units
represented by such Covered Interests) in addition to the consent of Lazard Ltd and LAZ-MD and (ii) with respect to Article III hereof (and the defined terms to the extent used therein), any amendment of the provisions of such article (and this
clause 5.2(a)(ii)) shall only require the affirmative vote of a majority of the outstanding Covered Interests (based on the number of units represented by such Covered Interests) and the consent of LAZ-MD; provided, that (1) with respect
to Article IV hereof (and the defined terms to the extent used therein), any amendment of the provisions of such article and this proviso shall only require the affirmative vote of 66 2/3% of the outstanding Covered Interests (based on the number of
units represented by such Covered Interests) and the consent of Lazard Ltd; and, (2) notwithstanding the foregoing, with respect to Article IV hereof (and the defined terms to the extent used therein), any amendment to the provisions of such
article that materially and adversely impacts the registration rights of any Covered Person set forth therein as in effect 

  

 19 

 
immediately prior to such amendment shall not be enforceable against that Covered Person unless that Covered Person consented to such amendment if such
amendment shall not apply to and affect the rights of all Covered Persons equally (for the avoidance of doubt, any such amendment shall not apply to and affect the rights of all Covered Persons equally if it affects the registration rights of
Covered Persons differently, including, without limitation, with respect to their employment status, length of employment or ownership (or right to acquire) of Registrable Securities) (it being understood and agreed that this clause (2) to the
proviso to Section 5.2(a) may not be amended without the consent of Lazard Ltd, LAZ-MD and each Covered Person). 
 (b)
In addition to any other vote or approval that may be required under this Section 5.2, any amendment of this Agreement that has the effect of changing the obligations of LAZ-MD or Lazard Ltd hereunder to make such obligations materially more
onerous to LAZ-MD or Lazard Ltd shall require the approval of LAZ-MD or Lazard Ltd, as the case may be. 
 (c) Each Covered
Person understands that it is intended that each Class II Member on the date hereof will be a Covered Person under this Agreement, and each Covered Person further understands that from time to time certain other persons may become Covered Persons
and certain Covered Persons will cease to be bound by the provisions of this Agreement pursuant to the terms hereof. This Agreement may be amended from time to time by LAZ-MD (without the approval of any other person), but solely for the purposes of
(i) adding to Appendix A such holders of Class II Interests and Permitted Transferees of the Covered Interests as provided in Section 5.1(c) in each case who sign this Agreement and (ii) removing from Appendix A such persons as shall
cease to be bound by the provisions of this Agreement pursuant to Sections 5.1(b) hereof, (which additions and removals pursuant to clauses (i) and (ii) of this sentence shall be given effect from time to time by appropriate changes to
Appendix A) and (iii) correcting any technicality, incorrect statement or error apparent on the face hereof in order to further the intent of the parties hereto. 
 (d) No provision of this Agreement may be waived except by an instrument in writing executed by the party against whom the waiver is to be
effective. 
 Section 5.3 GOVERNING LAW. THIS AGREEMENT SHALL BE GOVERNED BY AND CONSTRUED IN ACCORDANCE WITH THE LAWS OF THE STATE OF
DELAWARE, WITHOUT REGARD TO PRINCIPLES OF CONFLICTS OF LAWS. 
 Section 5.4 Resolution of Disputes. 
 (a) Notwithstanding anything herein to the contrary, each Covered Person shall have the right and power to seek enforcement of the
provisions contained in Article IV of this Agreement on behalf of such Covered Person against Lazard Ltd; provided, however, that LAZ-MD, in its sole discretion, may elect to assume, seek and conduct such enforcement on behalf of any such Covered
Persons with respect to any claims under Article IV, in which case such Covered Persons shall not have such enforcement right with respect to such claims for so long as LAZ-MD continues to conduct such enforcement and shall be fully bound by any
judgment or settlement with respect to any and all such claims assumed by LAZ-MD. 
 (b) All disputes arising under this
Agreement (each a “Disputes”) shall be determined in accordance with this Section 5.4. Each Dispute shall first be reviewed by the Board (“Board Review”). Any party to a Dispute may invoke Board Review by
written notice to the other party or parties thereto and the Board. As soon as practicable and in any event within thirty (30) days after receipt of notice of a Dispute, the Board shall attempt in good faith to resolve such Dispute. In the
event that any Dispute remains unresolved forty- five (45) days after notice thereof to the Board, such Dispute shall be finally determined by an arbitral tribunal under the Rules of Arbitration (the “ICC Rules”) of the
International Chamber of Commerce (the “ICC”) and in accordance with Section 5.4(c). 
 (c) The arbitral
tribunal determining any Dispute shall be comprised of three arbitrators. Each party to a Dispute shall designate one arbitrator. If a party fails to designate an arbitrator within a reasonable period, the ICC shall designate an arbitrator for such
party, including upon a request by another party. The two arbitrators designated by the parties to a Dispute (or, if applicable, the ICC) shall designate a third arbitrator. In the event 

  

 20 

 
that the two arbitrators designated by the parties to a Dispute (or, if applicable, the ICC) are unable to agree upon a third arbitrator within a reasonable
period, the third arbitrator shall be selected in accordance with the ICC Rules by the ICC. The language, place and procedures of the arbitration of any Dispute shall be as agreed upon by the parties to such Dispute or, failing such agreement within
a reasonable period, as determined in accordance with the ICC Rules in order to ensure a speedy, efficient and just resolution of such Dispute. If neither the parties nor the arbitral tribunal can agree upon procedures, the arbitration shall be
conducted in accordance with the ICC’s procedures. The hearings and taking of evidence of any Dispute may be conducted at any locations that will, in the judgment of the arbitral tribunal, result in a speedy, efficient and just resolution of
such Dispute. The parties to any dispute shall use their best efforts to cooperate with each other and the arbitral tribunal in order to obtain a resolution as quickly as possible, including by adopting the ICC’s “fast-track”
procedure (as provided for in Article 32(1) of the ICC Rules) if appropriate. 
 (d) Notwithstanding any provision of the
Agreement to the contrary, this Section 5.4(c) shall be construed to the maximum extent possible to comply with the laws of the State of Delaware, including the Uniform Arbitration Act (10 Del. C. § 5701 et seq.) (the “Delaware
Arbitration Act”). If, nevertheless, it shall be determined by a court of competent jurisdiction that any provision or wording of this Section 5.4(c), including the ICC Rules and any rules of the American Arbitration Association, shall
be invalid or unenforceable under the Delaware Arbitration Act, or other applicable law, such invalidity shall not invalidate all of this Section 5.4(c). In that case, this Section 5.4(c) shall be construed so as to limit any term or
provision so as to make it valid or enforceable within the requirements of the Delaware Arbitration Act or other applicable law, and, in the event such term or provision cannot be so limited, this Section 5.4(c) shall be construed to omit such
invalid or unenforceable provision. 
 (e) Notwithstanding the foregoing provisions, Lazard Ltd may bring, or may cause LAZ-MD
to bring, on behalf of Lazard Ltd or on behalf of one or more Covered Persons, an action or special proceeding in a state or federal court of competent jurisdiction sitting in the State of Delaware, whether or not an arbitration proceeding has
theretofore been or is ever initiated, for the purpose of temporarily, preliminarily or permanently enforcing the provisions of Article IV and, for the purposes of this paragraph (e), each Covered Person (i) expressly consents to the
application of paragraph (f) to any such action or proceeding, (ii) agrees that proof shall not be required that monetary damages for breach of the provisions of this Agreement would be difficult to calculate and that remedies at law would
be inadequate and (iii) irrevocably appoints the Board, c/o The Corporation Trust Company, Corporation Trust Center, 1209 Orange Street, Wilmington, Delaware 19801 as such Covered Person’s agent for service of process in connection with
any such action or proceeding, who shall promptly advise such Covered Person of any such service of process. 
 (f) EACH
COVERED PERSON HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF ANY STATE OR FEDERAL COURT LOCATED IN THE STATE OF DELAWARE OVER ANY SUIT, ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO OR CONCERNING THIS AGREEMENT THAT IS NOT
OTHERWISE ARBITRATED ACCORDING TO THE PROVISIONS OF PARAGRAPH (E) HEREOF. This includes any suit, action or proceeding to compel arbitration or to enforce an arbitration award. The parties acknowledge that the forum designated by this paragraph
(f) has a reasonable relation to this Agreement, and to the parties’ relationship with one another. Notwithstanding the foregoing, nothing herein shall preclude the LAZ-MD or Lazard Ltd from bringing any action or proceeding in any other
court for the purpose of enforcing the provisions of this Section 5.4. 
 (g) The agreement of the parties as to forum is
independent of the law that may be applied in the action, and they each agree to such forum even if the forum may under applicable law choose to apply non-forum law. The parties hereby waive, to the fullest extent permitted by applicable law, any
objection which they now or hereafter may have to personal jurisdiction or to the laying of venue of any such suit, action or proceeding brought in any court referred to in paragraph (f). The parties undertake not to commence any action arising out
of or relating to or concerning this Agreement pursuant to paragraph (e) in any forum other than a forum described in paragraph (f). The parties agree that, to the fullest extent permitted by applicable law, a final and non-appealable judgment
in any such suit, action or proceeding in any such court shall be conclusive and binding upon the parties. 
  

 21 

 Section 5.5 Relationship of Parties; Acknowledgements. 
 (a) The terms of this Agreement are intended not to create a separate entity for U.S. federal income tax purposes, and nothing in this
Agreement shall be read to create any partnership, joint venture or separate entity among the parties or to create any trust or other fiduciary relationship between them. 
 (b) Each Covered Person, by agreeing to become a party to this Agreement, acknowledges and agrees that such person is a member of each of
LAZ-MD and LFCM and bound by the terms of the Operating Agreement and the LFCM Operating Agreement, respectively. 
 Section 5.6 Transfer
Restrictions; Legends. 
 (a) General Restrictions on Transfer. Each Covered Person acknowledges and agrees that
the Covered Interests have not been registered under the Securities Act. Each Covered Person agrees that such person shall not Transfer any Covered Interests (or solicit any offers in respect of any Transfer of any Covered Interests), except in
compliance with the Securities Act, any other applicable securities or “blue sky” laws, and the terms and conditions of this Agreement and the Operating Agreement or the Lazard Group Operating Agreement, as applicable. Any attempt to
Transfer any Covered Interests not in compliance with this Agreement or the Operating Agreement or the Lazard Group Operating Agreement, as applicable, shall be null and void, and neither LAZ-MD nor Lazard Ltd, as the case may be, shall, and each of
them shall cause any transfer agent not to, give any effect in the applicable company’s stock records or equivalent limited liability company records to such attempted Transfer. 
 (b) Legends. Each Covered Person acknowledges that the following legend shall appear on the certificates for Covered Shares
reflecting the restrictions set forth in Section 5.6(a). Lazard Ltd shall, at the request of any Covered Person, remove from each certificate evidencing Covered Shares the following legend if Lazard Ltd is reasonably satisfied (based upon an
opinion of counsel to such Covered Person reasonably acceptable to Lazard Ltd) that the securities evidenced thereby may be publicly sold without registration under the Securities Act: 
 THIS SECURITY HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY FOREIGN OR STATE SECURITIES LAWS AND MAY NOT BE OFFERED, SOLD OR OTHERWISE DISPOSED OF EXCEPT (1) IN COMPLIANCE THEREWITH
OR (2) UPON THE FURNISHING TO LAZARD LTD BY THE HOLDER OF THIS CERTIFICATE AN OPINION OF COUNSEL REASONABLY ACCEPTABLE TO LAZARD LTD THAT SUCH TRANSACTION IS NOT REQUIRED TO BE REGISTERED UNDER APPLICABLE SECURITIES LAWS. 
 Section 5.7 Notices. 
 (a) Any communication, demand or notice to be given hereunder will be duly given (and shall be deemed to be received) when delivered in writing by hand or first class mail or by telecopy to a party at its address as indicated below:

 If to a Covered Person, 
 Name of Applicable Covered Person 
 c/o LAZ-MD Holdings LLC 
 30 Rockefeller Plaza 
 New York, New York 10020 
 Telecopy: (212) 332-5972 
 Attention: Board of Directors 
 If to LAZ-MD, at 
 LAZ-MD Holdings LLC 
 30 Rockefeller Plaza 
 New York, New York 10020 
 Telecopy: (212) 332-5972 
 Attention: Board of Directors 
  

 22 

 If to Lazard Ltd, at 
 Lazard Ltd 
 30 Rockefeller Plaza 
 New York, New York 10020 
 Telecopy: (212) 632-2000 
 Attention: General Counsel 
 LAZ-MD shall be responsible for notifying each Covered Person of the receipt of a
communication, demand or notice under this Agreement relevant to such Covered Person at the address of such Covered Person then in the records of LAZ-MD (and each Covered Person shall notify LAZ-MD of any change in such address for communications,
demands and notices). 
 (b) Unless otherwise provided to the contrary herein, any notice which is required to be given in
writing pursuant to the terms of this Agreement may be given by telecopy. 
 Section 5.8 Severability. If any provision of this
Agreement is finally held to be invalid, illegal or unenforceable, (a) the remaining terms and provisions hereof shall be unimpaired and (b) the invalid or unenforceable term or provision shall be deemed replaced by a term or provision
that is valid and enforceable and that comes closest to expressing the intention of the invalid or unenforceable term or provision. 
 Section 5.9 Specific Performance. Each party hereto acknowledges that the remedies at law of the other parties for a breach or threatened breach of this Agreement would be inadequate and, in recognition of this fact, any part to this
Agreement, without posting any bond, and in addition to all other remedies that may be available, shall, subject to Section 5.4, be entitled to obtain equitable relief in the form of specific performance, a temporary restraining order, a
temporary or permanent injunction or any other equitable remedy that may be then available. 
 Section 5.10 Assignment; Successors.
This Agreement shall be binding upon and inure to the benefit of the respective legatees, legal representatives, successors and assigns of the Covered Persons; provided, however, that a Covered Person may not assign this Agreement or
any of his rights or obligations hereunder, and any purported assignment in breach hereof by a Covered Person shall be void, without the prior written consent of each of LAZ-MD and Lazard Ltd; and provided further that no assignment of this
Agreement by LAZ-MD, Lazard Ltd or to a successor of LAZ-MD or Lazard Ltd (by operation of law or otherwise) shall be valid unless such assignment is made to a person which succeeds to the business of such Person substantially as an entirety.
Notwithstanding anything herein to the contrary, in the event of the liquidation or dissolution of LAZ-MD following the exchange of all Covered Interests, (a) references to LAZ-MD in this Section 5.10 and in Sections 5.1, 5.2 and 5.7 shall
be deemed to refer to Lazard Ltd, (b) references in Section 5.4 to LAZ-MD and the Board shall be deemed to refer to the person or persons designated by LAZ-MD for such purpose (with the consent of Lazard Ltd) and (c) references to the
Board in Section 5.4(e)(iii) shall be deemed to refer to the General Counsel of Lazard Ltd. 
 Section 5.11 No Third-Party
Rights. Other than as expressly provided herein, nothing in this Agreement will be construed to give any person other than the parties to this Agreement any legal or equitable right, remedy, or claim under or with respect to this Agreement or
any provision of this Agreement. This Agreement and all of its provisions and conditions are for the sole and exclusive benefit of the parties to this Agreement and their successors and assigns. 
 Section 5.12 Section Headings. The headings of sections in this Agreement are provided for convenience only and will not affect its construction
or interpretation. 
 Section 5.13 Execution in Counterparts. This Agreement may be executed in any number of counterparts, each of
which shall be deemed an original, but all such counterparts shall together constitute but one and the same instrument. 
  

 23 

 IN WITNESS WHEREOF, the parties hereto have duly executed or caused to be duly executed this Agreement as
of the dates indicated. 
  

			
	LAZ-MD HOLDINGS LLC
		
	By	 	/s/    LARRY GRAFSTEIN        
	Name:	 	Larry Grafstein
	Title:	 	Director
	
	LAZARD LTD (solely for the purposes of Articles I, II, IV and V hereto)
		
	By	 	/s/    MICHAEL J.
CASTELLANO        
	Name:	 	Michael J. Castellano
	Title:	 	Chief Financial Officer

  

 [Signature Page to Stockholders’ Agreement] 

	
	COVERED PERSON
	
	   
	Name:

  

 [Signature Page to Stockholders’ Agreement]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00112-of-00352.parquet"}]]